Staff

Ocugen to Host Conference Call on Friday, February 25 at 8:30 a.m. ET to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update

MALVERN, Pa., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and...

Ocugen, Inc. Announces U.S. FDA Lifts Clinical Hold on the Submission of Its Investigational New Drug Application for Its COVID-19 Vaccine Candidate COVAXIN™ (BBV152)

MALVERN, Pa., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing,...

Clinical Genomics Announces New Publication from Flinders Medical Centre, Highlighting the Use of COLVERA® as a Quantitative ctDNA Biomarker for Response to Colorectal Cancer Therapy

error: Content is protected !!